Abstract | BACKGROUND: Evidence is accumulating that a preclinical phase is present before the onset of clinical signs and symptoms of rheumatoid arthritis (RA). This phase represents an important therapeutic window within which interventions can dramatically modulate outcomes. An agent able to prevent RA for high risk individuals in this phase is therefore desired. In this study, we investigated whether tryptophan metabolite, 5-hydroxytryptophan (5-HTP) or 5-methoxytryptophan (5-MTP), can act as such an agent for primary prevention of collagen-induced arthritis (CIA). METHODS: RESULTS: CONCLUSIONS:
|
Authors | Tao-Hsiang Yang, Peng-Yang Hsu, Menghsiao Meng, Che-Chun Su |
Journal | Arthritis research & therapy
(Arthritis Res Ther)
Vol. 17
Pg. 364
(Dec 15 2015)
ISSN: 1478-6362 [Electronic] England |
PMID | 26669765
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Inflammation Mediators
- Collagen
- 5-Hydroxytryptophan
|
Topics |
- 5-Hydroxytryptophan
(administration & dosage)
- Animals
- Arthritis, Experimental
(drug therapy, metabolism, pathology)
- Cells, Cultured
- Collagen
- Dose-Response Relationship, Drug
- Inflammation
(drug therapy, metabolism, pathology)
- Inflammation Mediators
(antagonists & inhibitors, metabolism)
- Mice
- Mice, Inbred DBA
- Spleen
(cytology, drug effects, metabolism)
|